The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients

• Status: Completed
• Trial end date: 2022-01-06
• Target enrollment: 0
• Participant gender: All

Summary

The clinical and biochemical improvement observed in kidney transplant (RT) recipients is remarkable. The correct functioning of the allograft depends on various factors such as the donor's age, the alloimmune response, the ischemia-reperfusion injury, arterial hypertension, and the interstitial fibrosis of the allograft, among others. Antihypertensive drugs are necessary for arterial hypertension patients to avoid or reduce the probability of affecting graft function in RT recipients. Oxidative stress (OS) is another complex pathophysiological process with the ability to alter post-transplant kidney function. The study's objective was to determine the effect of the administration of Enalapril, Losartan, or not antihypertensive medication on the oxidative state in RT recipients at the beginning of the study and one year of follow-up.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Unidad de Investigacion Medica en Enfermedades Renales
• Treatments: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Enzyme Inhibitors; Losartan

Criteria

Inclusion Criteria:

• Renal trasplant, from a living related donor (DVR) or living unrelated donor (DVNoR)

• Who agreed to participate and signed the Letter of Consent under Information.

Exclusion Criteria:

• Patients who received an RT from a deceased donor,

• With donor >55 years,

• With renal comorbidities at the time of the study (urolithiasis, infections, diabetes),

• With blood dyscrasias,

• Second transplantation,

• Those with treatment with non-steroidal anti-inflammatory drugs,

• Treatment with statins, spironolactone, pentoxifylline, patients

• With neurodegenerative processes

• Those who withdrew the Letter of Consent under Information